Volanesorsen for treatment of familial chylomicronemia syndrome

References

• Laufs U, Parhofer KG, Ginsberg HN, et al. Clinical review on triglycerides. Eur Heart J. 2020;41:99–109.
   PubMed Web of Science ®Google Scholar
• Dron JS, Hegele RA. Genetics of hypertriglyceridemia. Front Endocrinol (Lausanne). 2020;11:455.
   PubMed Web of Science ®Google Scholar
• Huet F, Roubille C, Roubille F. Is hypertriglyceridemia atherogenic?. Curr Opin Lipidol. 2019;30:291–299.
   PubMed Web of Science ®Google Scholar
• Burnett JR, Hooper AJ, Hegele RA. Remnant cholesterol and atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2020;76:2736–2739.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
   PubMed Web of Science ®Google Scholar
• Sherratt SCR, Lero M, Mason RP. Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence. Curr Opin Lipidol. 2020 Apr;31(2):94–100.
   PubMed Web of Science ®Google Scholar
• Gill PK, Dron JS, Hegele RA. Genetics of hypertriglyceridemia and atherosclerosis. Curr Opin Cardiol. 2021;36:264–271.
   PubMed Web of Science ®Google Scholar
• Chait A, Eckel RH. The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment. Ann Intern Med. 2019;170:626–634. .
   PubMed Web of Science ®Google Scholar
• Dron JS, Wang J, McIntyre AD, et al. The polygenic nature of mild-to-moderate hypertriglyceridemia. J Clin Lipidol. 2020;14:28–34.
   PubMed Web of Science ®Google Scholar
• Dron JS, Wang J, Cao H, et al. Severe hypertriglyceridemia is primarily polygenic. J Clin Lipidol. 2019;13:80–88.
   PubMed Web of Science ®Google Scholar
• Dron JS, Wang J, McIntyre AD, et al. Six years’ experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias. BMC Med Genomics. 2020;13:23.
   PubMed Web of Science ®Google Scholar
• Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. Endocr Rev. 2015;36:131–147.
   PubMed Web of Science ®Google Scholar
• Brahm AJ, Hegele RA. Chylomicronaemia--current diagnosis and future therapies. Nat Rev Endocrinol. 2015;11:352–362.
   PubMed Web of Science ®Google Scholar
• Basu D, Goldberg IJ. Regulation of lipoprotein lipase-mediated lipolysis of triglycerides. Curr Opin Lipidol. 2020;31:154–160. .
   PubMed Web of Science ®Google Scholar
• Hegele RA, Berberich AJ, Ban MR, et al. Clinical and biochemical features of different molecular etiologies of familial chylomicronemia. J Clin Lipidol. 2018;12:920–927.
   PubMed Web of Science ®Google Scholar
• Sugandhan S, Khandpur S, Sharma VK. Familial chylomicronemia syndrome. Pediatr Dermatol. 2007;24:323–325.
   PubMed Web of Science ®Google Scholar
• Baass A, Paquette M, Bernard S, et al. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020;287:340–348.
   PubMed Web of Science ®Google Scholar
• Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”. Atherosclerosis. 2018;275:265–272.
   PubMed Web of Science ®Google Scholar
• Stroes E, Moulin P, Parhofer KG, et al. Diagnostic algorithm for familial chylomicronemia syndrome. Atheroscler Suppl. 2017;23:1–7.
   PubMed Web of Science ®Google Scholar
• O’Dea LSL, MacDougall J, Alexander VJ, et al. Differentiating familial chylomicronemia syndrome from multifactorial severe hypertriglyceridemia by clinical profiles. J Endocr Soc. 2019;3:2397–2410.
   PubMed Web of Science ®Google Scholar
• Valdivielso P, Ramirez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25:689–694.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Signorovitch J, Swallow E, et al. Medical resource use and costs associated with chylomicronemia. J Med Econ. 2013;16:657–666.
   PubMedGoogle Scholar
• Fredrickson DS, Lees RS. A System for phenotyping hyperlipoproteinemia. Circulation. 1965;31:321–327.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014;2:655–666.
   PubMed Web of Science ®Google Scholar
• Gotoda T, Shirai K, Ohta T, et al. Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb. 2012;19:1–12.
   PubMed Web of Science ®Google Scholar
• Pirillo A, Norata GD, Catapano AL. Postprandial lipemia as a cardiometabolic risk factor. Curr Med Res Opin. 2014;30:1489–1503.
   PubMed Web of Science ®Google Scholar
• Wang J, Cao H, Ban MR, et al. Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol. 2007;27:2450–2455.
   PubMed Web of Science ®Google Scholar
• Ashraf AP, Miyashita K, Nakajima K, et al. Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies. J Clin Lipidol. 2020;14:197–200.
   PubMed Web of Science ®Google Scholar
• Miyashita K, Lutz J, Hudgins LC, et al. Chylomicronemia from GPIHBP1 autoantibodies. J Lipid Res. 2020;61:1365–1376.
   PubMed Web of Science ®Google Scholar
• Welty FK. Dietary treatment to lower cholesterol and triglyceride and reduce cardiovascular risk. Curr Opin Lipidol. 2020;31:206–231. .
   PubMed Web of Science ®Google Scholar
• Hegele RA, Boren J, Ginsberg HN, et al. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020;8:50–67.
   PubMed Web of Science ®Google Scholar
• Davidson M, Stevenson M, Hsieh A, et al. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study. J Clin Lipidol. 2018;12:898–907.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Tsimikas S. Lipid-lowering agents. Circ Res. 2019;124:386–404.
   PubMed Web of Science ®Google Scholar
• Gryn SE, Hegele RA. New oral agents for treating dyslipidemia. Curr Opin Lipidol. 2016;27:579–584.
   PubMed Web of Science ®Google Scholar
• Kassner U, Hollstein T, Grenkowitz T, et al. Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice Conditions. Hum Gene Ther. 2018;29:520–527.
   PubMed Web of Science ®Google Scholar
• Senior M. After Glybera’s withdrawal, what’s next for gene therapy?. Nat Biotechnol. 2017;35:491–492.
   PubMed Web of Science ®Google Scholar
• Huff MW, Hegele RA. Apolipoprotein C-III: going back to the future for a lipid drug target. Circ Res. 2013;112:1405–1408.
   PubMed Web of Science ®Google Scholar
• Maeda H, Hashimoto RK, Ogura T, et al. Molecular cloning of a human apoC-III variant: Thr 74----Ala 74 mutation prevents O-glycosylation. J Lipid Res. 1987;28:1405–1409.
   PubMed Web of Science ®Google Scholar
• Qin W, Sundaram M, Wang Y, et al. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. J Biol Chem. 2011;286:27769–22780.
   PubMed Web of Science ®Google Scholar
• Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol. 1999;19:472–484.
   PubMed Web of Science ®Google Scholar
• McConathy WJ, Gesquiere JC, Bass H, et al. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res. 1992;33:995–1003.
   PubMed Web of Science ®Google Scholar
• Huff MW, Fidge NH, Nestel PJ, et al. Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects. J Lipid Res. 1981;22:1235–1246.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 2000;102:1886–1892.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Connelly PW, Hanley AJ, et al. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol. 1997;17:2753–2758.
   PubMed Web of Science ®Google Scholar
• Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702–1705.
   PubMed Web of Science ®Google Scholar
• TG HDL. Working Group of the Exome Sequencing Project NHLBI, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22–31.
   PubMed Web of Science ®Google Scholar
• Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32–41.
   PubMed Web of Science ®Google Scholar
• Hansen SEJ, Madsen CM, Varbo A, et al.. Genetic variants associated with increased plasma levels of triglycerides, via effects on the lipoprotein lipase pathway, increase risk of acute pancreatitis. Clin Gastroenterol Hepatol. 2020 Aug 12;S1542-3565(20)31125-3. DOI:10.1016/j.cgh.2020.08.016.
   Google Scholar
• Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012;226:365–379.
   PubMed Web of Science ®Google Scholar
• Levin AA. Treating disease at the RNA level with oligonucleotides. N Engl J Med. 2019;380:57–70. .
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia. Atheroscler Suppl. 2017;30:19–27.
   PubMed Web of Science ®Google Scholar
• Chan L, Yokota T. Development and clinical applications of antisense oligonucleotide gapmers. Methods Mol Biol. 2020;2176:21–47. .
   PubMedGoogle Scholar
• Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112:1479–1490.
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Viljoen A. Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. Expert Opin Biol Ther. 2016;16:1125–1134.
   PubMed Web of Science ®Google Scholar
• Aslesh T, Yokota T. Development of antisense oligonucleotide gapmers for the treatment of dyslipidemia and lipodystrophy. Methods Mol Biol. 2020;2176:69–85.
   PubMedGoogle Scholar
• Gaudet D, Brisson D, Tremblay K, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;371:2200–2206.
   PubMed Web of Science ®Google Scholar
• Ueda M, Wolska A, Burke FM, et al. Experimental therapeutics for challenging clinical care of a patient with an extremely rare homozygous APOC2 mutation. Case Rep Endocrinol. 2020;2020:1865489.
   PubMed Web of Science ®Google Scholar
• Gordts PLSM, Nock R, Son N-H, et al.. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest. 2016;126:2855–2866.
   PubMed Web of Science ®Google Scholar
• Witztum JL, Gaudet D, Freedman SD, et al.. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531–542.
   PubMed Web of Science ®Google Scholar
• Arca M, Hsieh A, Soran H, et al. The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study. Expert Rev Cardiovasc Ther. 2018;16:537–546.
   PubMed Web of Science ®Google Scholar
• Gouni-Berthold I, Alexander VJ, Yang Q, et al. Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9:264–275.
   PubMed Web of Science ®Google Scholar
• Digenio A, Dunbar RL, Alexander VJ, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39:1408–1415.
   PubMed Web of Science ®Google Scholar
• Fogacci F, Norata GD, Toth PP, et al. Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. Curr Atheroscler Rep. 2020;22(5):18.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Baker BF, Witztum JL, et al. The effects of 2ʹ-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials. Nucleic Acid Ther. 2017;27:121–129.
   PubMed Web of Science ®Google Scholar
• Reeskamp LF, Tromp TR, Stroes ESG. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?. Curr Opin Lipidol. 2020;31:140–146.
   PubMed Web of Science ®Google Scholar
• Alexander VJ, Xia S, Hurh E, et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 2019;40:2785–2796.
   PubMed Web of Science ®Google Scholar
• Ganda OP. When to lower triglycerides?. Curr Opin Lipidol. 2020;31:238–245.
   PubMed Web of Science ®Google Scholar
• Wolska A, Yang ZH, Remaley AT. Hypertriglyceridemia: new approaches in management and treatment. Curr Opin Lipidol. 2020;31:331–339.
   PubMed Web of Science ®Google Scholar
• Wolska A, Reimund M, Remaley AT. Apolipoprotein C-II: the re-emergence of a forgotten factor. Curr Opin Lipidol. 2020;31:147–153.
   PubMed Web of Science ®Google Scholar